• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma

by | Mar 18, 2025 | Uncategorized

Source: CureToday articles Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma. Read More

First relapse in multiple myeloma: the patient perspective

by | Mar 18, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease

by | Mar 14, 2025 | Uncategorized

Source: CureToday articles Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month. Read More

Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma

by | Mar 10, 2025 | Uncategorized

Source: CureToday articles Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE. Read More

The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma

by | Feb 18, 2025 | Uncategorized

Source: CureToday articles The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma. Read More

Unexpected Support in Tough Times With Multiple Myeloma

by | Feb 11, 2025 | Uncategorized

Source: CureToday articles Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me. Read More
« Older Entries
Next Entries »

Recent Content

  • EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
  • Patient-reported physical function has ‘real clinical value’ for treating multiple myeloma
  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT